Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma

References

• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave S, et al. Gene expression signatures predict survival in diffuse large B cell lymphoma following rituximab and CHOP-like chemotherapy. Ann Oncol. 2008;19:93.
   Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29:200–207.
   PubMed Web of Science ®Google Scholar
• Read JA, Koff JL, Nastoupil LJ, et al. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14:460–467.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined With R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2015;33:251–257.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Kolibaba K, Reeves JA, et al. Randomized phase 2 open-label study of R-CHOP ± bortezomib in patients (pts) with untreated non-germinal center B-cell-like (non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the pyramid trial (NCT00931918). Blood. 2015;126:811–811.
   Web of Science ®Google Scholar
• Celgene corporation. Efficacy and safety study of lenalidomide plus R-CHOP chemotherapy versus placebo plus R-CHOP chemotherapy in untreated ABC type diffuse large B-cell lymphoma (ROBUST). In clinicaltrials.gov; 2014 [cited 2016 Jan 28]; Available from: https://clinicaltrials.gov/ct2/show/NCT02285062?term=lenalidomide+ROBUST&rank = 1
   Google Scholar
• Janssen research & development. A study of the bruton's tyrosine kinase inhibitor, PCI-32765 (Ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma. In clinicaltrials.gov; 2013 [cited 2016 Feb 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01855750
   Google Scholar
• Case comprehensive cancer center. Carfilzomib, rituximab, and combination chemotherapy in treating patients with diffuse large B-cell lymphoma. In clinicaltrials.gov. Case comprehensive cancer center; 2014 [cited 2014 June 11]. Available from: http://clinicaltrials.gov/ct2/show/NCT02073097?term=carfilzomib+R-CHOP&rank = 1
   Google Scholar
• Millennium Pharmaceuticals. 2014 2/16/2016. Study to assess the effectiveness of RCHOP with or without VELCADE in previously untreated non-germinal center B-cell-like diffuse large B-cell lymphoma patients. In clinicaltrials.gov; 2014 [cited 2016 Feb 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT00931918
   Google Scholar
• Elkin EB, Marshall DA, Kulin NA, et al. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011;13:853–860.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15:415–453.
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Smith SM. Management of relapsed diffuse large B-cell lymphoma. Curr Oncol Rep. 2008;10:393–403.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079–4087.
   PubMed Web of Science ®Google Scholar
• SEER. Surveillance, Epidemiology, and End results (SEER) program (www.seer.cancer.gov) Research Data (1973–2011), based on the November 2013 submission. Surveillance Research Program SSB; National Cancer Institute, DCCPS; 2014.
   Google Scholar
• The bureau of labor statistics. Archived Consumer Price Index detailed report information; 2015 [cited 2015 July 1]. Available at: http://www.bls.gov/cpi/cpi_dr.htm
   Google Scholar
• Tumeh JW, Moore SG, Shapiro R, et al. Practical approach for using medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2005;5:153–162.
   PubMedGoogle Scholar
• Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a united states–based cost-effectiveness analysis. J Clin Oncol. 2015;33:1112–1118.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. ASP drug pricing files; 2016 [cited 2016 Feb]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles.html
   Google Scholar
• Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626–633.
   PubMed Web of Science ®Google Scholar
• Slodkowska EA, Ross JS. MammaPrint™ 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009;9:417–422.
   PubMed Web of Science ®Google Scholar
• Roberts MC, Dusetzina SB. Use and costs for tumor gene expression profiling panels in the management of breast cancer from 2006 to 2012: implications for genomic test adoption among private payers. J Periodontol. 2015;11:273–277.
   Google Scholar
• Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health. 2005;8:462–470.
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton C, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2006.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–797.
   PubMed Web of Science ®Google Scholar
• Davies AJ, Caddy J, Maishman T, et al. A prospective randomised trial of targeted therapy for diffuse large B-cell lymphoma (DLBCL) based upon real-time gene expression profiling: the remodl-B study of the UK NCRI and SAKK lymphoma groups. Blood. 2015;126:812–812.
   Web of Science ®Google Scholar
• Wilson WH, sin-Ho J, Pitcher BN, et al. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/alliance 50303. Blood. 2016;128:469.
   Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Development and validation of biopsy-free genotyping for molecular subtyping of diffuse large B-cell lymphoma. Blood. 2016;128:1089.
   Web of Science ®Google Scholar
• Staiger AM, Ziepert M, Horn H, et al. The clinical impact of the cell-of-origin classification and the MYC+/BCL2+ double expresser status in DLBCL treated within prospective clinical trials of the Dshnhl. Blood. 2016;128:151.
   Web of Science ®Google Scholar
• Zhang J, Reddy A, Love C, et al. Integrative genetic and clinical analysis through whole exome sequencing in 1001 diffuse large B cell lymphoma (DLBCL) patients reveals novel disease drivers and risk groups. Am Soc Hematology. 2016;128:1087.
   Google Scholar
• Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35:2473–2481.
   PubMed Web of Science ®Google Scholar
• Romanus D, Cardarella S, Cutler D, et al. Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J Thoracic Oncol. 2015;10:586–594.
   PubMed Web of Science ®Google Scholar
• Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25:625–633.
   PubMed Web of Science ®Google Scholar
• Roberts MC, Dusetzina SB. Use and costs for tumor gene expression profiling panels in the management of breast cancer from 2006 to 2012: implications for genomic test adoption among private payers. J Oncol Pract. 2015;4:273–277.
   Web of Science ®Google Scholar
• Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–1217.
   PubMed Web of Science ®Google Scholar
• Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33:2848–2856.
   PubMed Web of Science ®Google Scholar
• Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer. 2012;118:5163–5170.
   PubMed Web of Science ®Google Scholar
• Majhail NS, Mau L-W, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant. 2013;48:294–300.
   PubMed Web of Science ®Google Scholar